We are pleased to present the January issue of Dechert LLP’s UK Life Sciences and Healthcare Newsletter.
This month's Newsletter provides an insight into current developments, analysis and news, including:
- An update in relation to the recently published report by the European Union Intellectual Property Office and Organisation for Economic Co-Operation and Development regarding counterfeit pharmaceuticals
- An update on the UK government's recent launch of a consultation into potential reforms to post-termination non-compete clauses in employment contracts
- A panel discussion on the healthcare investment landscape post COVID-19
- A guest contributor feature from AXA IM Framlington's Co-head of Global Equities Linden Thomson: "All Eyes Were on Biotech in 2020: Some Investor Observations"
Read the 'UK Life Sciences and Healthcare Newsletter.'